Publications

Journal Article
Review Research Support, Non-U.S. Gov't
Ppublish 105 citations
Electronic publication date
November 18, 2022

View on Pubmed.gov 33979675 | View on doi.org 10.1016/j.semca...

Bacteria as a treasure house of secondary metabolites with anticancer potential.

Search for publications in this journal Semin Cancer Biol - 86(Pt 2):998-1013

Abstract

Cancer stands in the frontline among leading killers worldwide and the annual mortality rate is expected to reach 16.4 million by 2040. Humans suffer from about 200 different types of cancers and many of them have a small number of approved therapeutic agents. Moreover, several types of major cancers are diagnosed at advanced stages as a result of which the existing therapies have limited efficacy against them and contribute to a dismal prognosis. Therefore, it is essential to develop novel potent anticancer agents to counteract cancer-driven lethality. Natural sources such as bacteria, plants, fungi, and marine microorganisms have been serving as an inexhaustible source of anticancer agents. Notably, over 13,000 natural compounds endowed with different pharmacological properties have been isolated from different bacterial sources. In the present article, we have discussed about the importance of natural products, with special emphasis on bacterial metabolites for cancer therapy. Subsequently, we have comprehensively discussed the various sources, mechanisms of action, toxicity issues, and off-target effects of clinically used anticancer drugs (such as actinomycin D, bleomycin, carfilzomib, doxorubicin, ixabepilone, mitomycin C, pentostatin, rapalogs, and romidepsin) that have been derived from different bacteria. Furthermore, we have also discussed some of the major secondary metabolites (antimycins, chartreusin, elsamicins, geldanamycin, monensin, plicamycin, prodigiosin, rebeccamycin, salinomycin, and salinosporamide) that are currently in the clinical trials or which have demonstrated potent anticancer activity in preclinical models. Besides, we have elaborated on the application of metagenomics in drug discovery and briefly described about anticancer agents (bryostatin 1 and ET-743) identified through the metagenomics approach.

References

No references provided.

Cited by 105 citations (total)

Journal Article

Identification of a l-Threonine-Utilizing Hydrazine Synthetase for Thrazarine Biosynthesis in Streptomyces coerulescens MH802-fF5.

Electronic publication date June 26, 2025

Search for publications in this journal Chembiochem

Yusuke Shikai [...] Yasuo Ohnishi et al.

Hydrazine synthetases (HSs), consisting of cupin and methionyl-tRNA synthetase (MetRS)-like domains, catalyze hydrazine formation in the biosynthesis of various nitrogennitrogen...

Journal Article

Characterization of soil-derived Bacillus subtilis metabolites against breast cancer: In vitro and in silico studies.

Electronic publication date May 21, 2025

Search for publications in this journal Saudi Pharm J

Ayesha Irfan Hashmi [...] Muhammad Athar Abbasi et al.

Breast cancer remains one of the most challenging and widespread cancers among women globally that warrants further investigations for novel...

Conflict of interest statement

Declaration of Competing Interest There is no conflict of interests to declare.

MeSH

Specialties

Substances

Copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.